fouremm, any thoughts on how Don and Company would go about selling off 20% of Zenith Epigenetic's Ltd., formula ZEN-3694? What would that look like? Would that be in the form of a 20% Private placement in ZCC? With so many potential candidates/collaborators with so many clinical trials ongoing, and with some success, licencing ZEN-3694 in succession makes more sense in the long term. If you sell 20% interest to one entity, would it be fair to other candidates/collaborators with so many clinical trials still ongoing? 

Koo